This document compares the effectiveness of prednisone and infliximab in treating Crohn's disease. Prednisone is a steroid that reduces inflammation but has side effects. Infliximab is an antibody that neutralizes TNF-α to reduce inflammation. A clinical trial found that maintenance treatment with infliximab every 8 weeks was more effective at maintaining remission and reducing steroid use than prednisone alone. However, infliximab also carries risks of infection that must be considered. Overall, the document analyzes the mechanisms and effectiveness of different pharmacological therapies for Crohn's disease.